China’s CDE Expects More New Drugs with Accelerated Approval
The newly released 2021 Drug Review Annual Report by China’s Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) data shows that China has achieved doubling of drug approvals in 2021 compared to prior year. More importantly, it suggests the determination of Chinese authority to encourage more New Drugs to the market by…